Dendritic cell vaccines for melanoma: past, present and future.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2016-12-01 Epub Date: 2016-11-29 DOI:10.2217/mmt-2016-0014

Robert O Dillman, Gabriel I Nistor, Andrew N Cornforth

引用次数: 22

Abstract

Administering dendritic cells (DC) loaded with tumor-associated antigens (TAA) ex vivo is a promising strategy for therapeutic vaccines in advanced melanoma. To date the induction of immune responses to specific TAA has been more impressive than clinical benefit because of TAA limitations, suboptimal DC and possibly immune-checkpoint inhibition. Various products, antigen-loading techniques, treatment schedules, routes of administration and adjunctive agents continue to be explored. Biologic heterogeneity suggests autologous tumor as the optimal TAA source to induce immune responses to the entire repertoire of unique patient-specific neoantigens. Many questions remain regarding the optimal preparation of DC and strategies for antigen loading. Effective DC vaccines should result in additive or synergistic effects when combined with checkpoint inhibitors.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

黑色素瘤树突状细胞疫苗：过去、现在和未来。

体外给予负载肿瘤相关抗原（TAA）的树突状细胞（DC）是晚期黑色素瘤治疗疫苗的一种有前途的策略。迄今为止，由于TAA的局限性、次优DC以及可能的免疫检查点抑制，对特定TAA的免疫反应诱导比临床益处更令人印象深刻。各种产品、抗原装载技术、治疗方案、给药途径和辅助剂仍在继续探索中。生物学异质性表明，自体肿瘤是诱导对整个独特的患者特异性新抗原库的免疫反应的最佳TAA来源。关于DC的最佳制备和抗原负载策略，仍然存在许多问题。当与检查点抑制剂联合使用时，有效的DC疫苗应产生相加或协同作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.